4.6 Article

COINFECTION AND MORTALITY IN PNEUMONIA-RELATED ACUTE RESPIRATORY DISTRESS SYNDROME PATIENTS WITH BRONCHOALVEOLAR LAVAGE: A PROSPECTIVE OBSERVATIONAL STUDY

Journal

SHOCK
Volume 47, Issue 5, Pages 615-620

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SHK.0000000000000802

Keywords

Acute respiratory distress syndrome; bronchoalveolar lavage; coinfection; outcomes; pneumonia

Ask authors/readers for more resources

Background: Pneumonia is the leading risk factor of acute respiratory distress syndrome (ARDS). It is increasing studies in patients with pneumonia to reveal that coinfection with viral and bacterial infection can lead to poorer outcomes than no coinfection. This study evaluated the role of coinfection identified through bronchoalveolar lavage (BAL) examination on the outcomes of pneumonia-related ARDS. Methods: We performed a prospective observational study at Chang Gung Memorial Hospital from October 2012 to May 2015. Adult patients were included if they met the Berlin definition of ARDS. The indications for BAL were clinically suspected pneumonia-related ARDS and no definite microbial sample identified from tracheal aspirate or sputum. The presence of microbial pathogens and clinical outcomes were analyzed. Results: Of the 19,936 patients screened, 902 (4.5%) fulfilled the Berlin definition of ARDS. Of these patients, 255 (22.7%) had pneumonia-related ARDS and were included for analysis. A total of 142 (55.7%) patients were identified to have a microbial pathogen through BAL and were classified into three groups: a virus-only group (n = 41 [28.9%]), no virus group (n = 60 [42.2%]), and coinfection group (n = 41 [28.9%]). ARDS severity did not differ significantly between the groups (P = 0.43). The hospital mortality rates were 53.7% in virus-only identified group, 63.3% in no virus identified group, and 80.5% in coinfection identified group. The coinfection group had significantly higher mortality than virus-only group (80.5% vs. 53.7%; P = 0.01). Conclusion: In patients with pneumonia-related ARDS, the BAL pathogen-positive patients had a trend of higher mortality rate than pathogen-negative patients. Coinfection with a virus and another pathogen was associated with increased hospital mortality in pneumonia-related ARDS patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, General & Internal

Circulating Tumor Cells as a Tool of Minimal Residual Disease Can Predict Lung Cancer Recurrence: A longitudinal, Prospective Trial

Ching-Yang Wu, Chia-Lin Lee, Ching-Feng Wu, Jui-Ying Fu, Cheng-Ta Yang, Chi-Tsung Wen, Yun-Hen Liu, Hui-Ping Liu, Jason Chia-Hsun Hsieh

DIAGNOSTICS (2020)

Review Oncology

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)

Ping-Chih Hsu, Cheng-Ta Yang, David M. Jablons, Liang You

CANCERS (2020)

Article Chemistry, Medicinal

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study

Ping-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, Scott Chih-Hsi Kuo, Chia-Hsun Chu, Pi-Hung Tung, Allen Chung-Cheng Huang, Chih-Liang Wang, Li-Chung Chiu, Yueh-Fu Fang, Cheng-Ta Yang

PHARMACEUTICALS (2020)

Article Oncology

Predictors of Invasive Adenocarcinomas among Pure Ground-Glass Nodules Less Than 2 cm in Diameter

Wen-Chi Hsu, Pei-Ching Huang, Kuang-Tse Pan, Wen-Yu Chuang, Ching-Yang Wu, Ho-Fai Wong, Cheng-Ta Yang, Yung-Liang Wan

Summary: Benign lesions, atypical adenomatous hyperplasia, and malignancies such as adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive adenocarcinoma may present as pure ground-glass nodules on chest CT images. The prognosis of patients with invasive adenocarcinoma is worse than others. The presence of an air cavity is a significant predictor of invasive adenocarcinoma in pure ground-glass nodules.

CANCERS (2021)

Review Immunology

Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

Li-Chung Chiu, Shu-Min Lin, Yu-Lun Lo, Scott Chih-Hsi Kuo, Cheng-Ta Yang, Ping-Chih Hsu

Summary: Early-stage NSCLC patients face high risks of recurrence and death even after surgery, with limited improvements from traditional treatments like chemotherapy and radiation. Immunotherapies, including immune checkpoint inhibitors and cancer vaccination, have shown potential in improving survival rates and are being actively researched in clinical trials.

VACCINES (2021)

Article Microbiology

Relative COVID-19 Viral Persistence and Antibody Kinetics

Chung-Guei Huang, Avijit Dutta, Ching-Tai Huang, Pi-Yueh Chang, Mei-Jen Hsiao, Yu-Chia Hsieh, Shu-Min Lin, Shin-Ru Shih, Kuo-Chien Tsao, Cheng-Ta Yang

Summary: During the initial outbreak in Taiwan, some COVID-19 patients experienced delayed virus clearance, possibly due to the presence of excessive but compromised antibodies in the early stage. These patients had higher levels of serum antibodies, which might affect the effectiveness of virus clearance.

PATHOGENS (2021)

Article Oncology

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu

Summary: A novel nomogram was created in this study to help physicians suggest the optimal treatment for EGFRm+ NSCLC patients. The nomogram was based on pretreatment factors and stratified patients into five different risk groups for progression-free survival (PFS) and overall survival (OS). This risk stratification can provide additional information for clinicians and patients in determining the optimal therapeutic options.

CANCERS (2022)

Article Oncology

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang

Summary: This study reviewed the clinical outcomes and safety of EGFR-TKI treatment in lung adenocarcinoma patients with poor performance status and identified independent prognostic factors. The results showed that patients treated with 40 mg afatinib had better survival outcomes and dose adjustment was an independent prognostic factor for both progression-free survival and overall survival. This study provided evidence and prognostic factors for the use of EGFR-TKIs in patients with poor performance status.

CANCERS (2022)

Article Immunology

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study

Chin-Chou Wang, Li-Chung Chiu, Jia-Shiuan Ju, Yu-Ching Lin, Yueh-Fu Fang, Cheng-Ta Yang, Ping-Chih Hsu

Summary: The study found that consolidation durvalumab is effective and safe for post-CCRT unresectable stage III NSCLC in clinical practice, but EGFR mutation is an unfavorable factor for consolidation durvalumab therapy. Therefore, it is necessary to search for a better consolidation therapy for patients with EGFR mutations.

VACCINES (2021)

Article Cell Biology

Nuclear p120 catenin is a component of the perichromosomal layer and coordinates sister chromatid segregation during mitosis in lung cancer cells

Shu-Er Chow, Yaa-Jyuhn J. Meir, Jhy-Ming Li, Ping-Chih Hsu, Cheng-Ta Yang

Summary: This study investigates the dynamic changes in nuclear p120 catenin localization during cell cycle progression, revealing its role in the formation of the chromosome periphery and its interaction with lumican. Furthermore, it validates the protective role of p120 catenin in maintaining chromosome integrity.

CELL DEATH & DISEASE (2022)

Article Oncology

Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab

How-Wen Ko, Chi-Tsun Chiu, Chih-Liang Wang, Tsung-Ying Yang, Chien-Ying Liu, Chih-Teng Yu, Li-Chuan Tseng, Chih-Hsi Scott Kuo, Chin-Chou Wang, Muh-Hwa Yang, Cheng-Ta Yang

Summary: This study demonstrated the beneficial effect of denosumab treatment on the overall survival of NSCLC patients with bone metastasis and EGFR mutations. Denosumab also prolonged the SRE-free survival in patients without initial skeletal-related events and improved the overall survival of those with initial or pre-existing events.

CANCERS (2022)

Article Biotechnology & Applied Microbiology

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies

Satoru Miura, Hyun Ae Jung, Shin Yup Lee, Seung Hyeun Lee, Min Ki Lee, Yong Chul Lee, Maximilian J. Hochmair, Cheng-Ta Yang, Angela Marten, James Chih-Hsin Yang, Sanjay Popat

Summary: Sequential afatinib/osimertinib treatment showed promising activity in Asian patients with EGFR mutation-positive NSCLC, especially those with Del19-positive disease. This treatment was effective in real-world patients, including those with T790M-mediated acquired resistance and poor ECOG PS or brain metastases.

ONCOTARGETS AND THERAPY (2022)

Article Oncology

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients

Yan-Jei Tang, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Ping-Chih Hsu, Chiao-En Wu

Summary: This study confirmed the greater efficacy of later-line osimertinib for NSCLC with acquired T790M mutation than for NSCLC without acquired T790M mutation. Detection of the T790M mutation after frontline treatment is crucial for prolonging the survival of NSCLC patients. Osimertinib may be considered an option for NSCLC with unknown T790M mutations.

CANCERS (2022)

Article Medicine, General & Internal

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports

Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang

Summary: Anti-PD-1/PD-L1 immune checkpoint inhibitors combined with bevacizumab and platinum-based chemotherapy have shown promising efficacy in treating metastatic non-squamous cell lung cancer. However, drug-induced nephrotoxicity is a rare but serious adverse effect that requires careful evaluation and management.

CLINICS AND PRACTICE (2023)

Article Medicine, General & Internal

Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease

Li-Chung Chiu, Ping-Chih Hsu, Tzung-Hai Yen, Scott Chih-Hsi Kuo, Yueh-Fu Fang, Yu-Lun Lo, Shu-Min Lin, Cheng-Ta Yang, Chung-Shu Lee

Summary: The study found a significant association between blood cadmium levels and oxygen desaturation during the 6MWT in COPD patients, with the high-blood cadmium group exhibiting significantly higher levels of desaturation than the low-blood cadmium group.

MEDICINA-LITHUANIA (2021)

No Data Available